We explain why credit investors cannot just rely on rates and diversification for protection and discuss the tools that support capital preservation during market sell-offs.

We explain why credit investors cannot just rely on rates and diversification for protection and discuss the tools that support capital preservation during market sell-offs.
As we move into Q2, FSA wishes everyone well on the Easter holidays.
Schroders creates Singapore CEO role; Fund buyers look at alts; Chinese companies lack ESG policies; and more…
All portfolios had their steepest monthly declines in March since the coronavirus outbreak started.
Gareth Wilde, Managing director, Asia shares a video update with our clients during this challenging time in the region.
This week FSA presents a quick comparison of two Greater China equity products: the NB China Equity Fund and the Value Partners Classic Fund.
This week FSA presents a quick comparison of two North America equity products: the SJP North American Fund and the Wells Fargo Worldwide US All Cap Growth Fund.
Disease treatment is changing rapidly, leading to new therapies and better long-term results for patients — and creating investment opportunities, according to Andy Acker, portfolio manager, Janus Henderson Global Life Sciences and Dan Lyons, research analyst.
As global markets tumbled last month, all aggressive portfolios had steep declines in February but still beat their respective benchmarks.
This week FSA presents a quick comparison of two Greater China equity products: the AB China Opportunity Portfolio Fund and the New Capital China Equity Fund.
Part of the Mark Allen Group.